Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.jcin.2024.09.064 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Transcatheter Tricuspid Valve Clinical Trials: Incomplete Data and FDA-Approved Devices.
Struct Heart
November 2024
Department of Cardiovascular Medicine, Intermountain Medical Center, Murray, UT.
Each reviewed trial of transcatheter tricuspid valve intervention demonstrated clinically meaningful improvement in Kansas City Cardiomyopathy Questionnaire (KCCQ)-defined quality of life and favorable right ventricular remodeling. KCCQ correlates with tricuspid regurgitation (TR) reduction, heart failure hospitalization, and mortality. Change in KCCQ is therefore meaningful both as a measure of quality of life and as a surrogate endpoint of the impact of TV interventions.
View Article and Find Full Text PDFEVOQUE Transcatheter Tricuspid Valve Replacement: 5 Years On.
JACC Cardiovasc Interv
December 2024
Structural Heart Program, St. Michael's Hospital, University of Toronto, Toronto, Ontario, Canada.
Transjugular Transcatheter Tricuspid Valve Replacement With EVOQUE.
JACC Cardiovasc Interv
December 2024
Structural Heart Program, St. Michael's Hospital, University of Toronto, Toronto, Ontario, Canada. Electronic address:
Transcatheter Tricuspid Valve Replacement Following Tricuspid Edge-To-Edge-Repair.
Catheter Cardiovasc Interv
January 2025
Department of Cardiology and Angiology, University Hospital Tübingen, Otfried-Müller-Straße 10, Tübingen, Baden-Württemberg, Germany.
Significant tricuspid regurgitation (TR) is seen as a relevant contributor of cardiac morbidity and mortality. Transcatheter tricuspid valve replacement (TTVR) is a novel technique to treat this condition. We present the case of an 82-year-old lady who was admitted for recurrent right heart decompensation despite having undergone treatment with tricuspid edge-to-edge repair (TEER).
View Article and Find Full Text PDFComplete heart block and subsequent sudden cardiac death following transcatheter tricuspid valve replacement in a heart transplant patient: a case report.
Eur Heart J Case Rep
December 2024
Department of Medicine, Western University, London, ON N6A 5W9, Canada.
Article Synopsis
- Tricuspid regurgitation (TR) is a common issue after heart transplantation, and a new treatment called transcatheter tricuspid valve replacement (TTVR) has emerged, although it comes with risks.
- A 46-year-old woman who underwent a heart transplant developed severe TR, had a TTVR procedure, but later suffered from cardiogenic shock and sudden cardiac death, linked to complications in the area of her heart's electrical conduction system.
- This case highlights the dangers of TTVR in heart transplant patients, emphasizing the need for close monitoring due to the potential for serious heart rhythm issues like complete heart block.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!